

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)



(10) International Publication Number
WO 2022/094082 A1

(51) International Patent Classification:

A61P 17/00 (2006.01) A61K 47/20 (2006.01)

A61K 9/00 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/US2021/057052

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

28 October 2021 (28.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/106,983 29 October 2020 (29.10.2020) US

(71) Applicant: **ARCUTIS BIOTHERAPEUTICS, INC.**

[US/US]; 3027 Townsgate Road, Suite #300, Westlake Village, CA 91361 (US).

(72) Inventors: **HIGHAM, Robert**; c/o Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite #300, Westlake Village, CA 91361 (US). **BERK, David**; c/o Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite #300, Westlake Village, CA 91361 (US). **WATANABE, Frank**; c/o Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite #300, Westlake Village, CA 91361 (US).

(74) Agent: **POSTAL, Brett, A.**; Rothwell, Figg, Ernst & Manbeck, P.C., 607 14th Street NW, Suite 800, Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR TREATING VITILIGO LESIONS HAVING IMPROVED EFFICACY

(57) Abstract: Methods for treating vitiligo lesions including administering to a patient having vitiligo lesions a combination of a topical treatment and ultraviolet B ("UVB") phototherapy. As disclosed herein, the inventors of the present invention have made the surprising discovery that the JAK inhibitor SHR0302 applied topically combined with narrowband UVB phototherapy dramatically repigments vitiligo lesions, including vitiligo lesions of the face and neck.

WO 2022/094082 A1